Allurion Catapults 132% On Its Plans To Outdo Eli Lilly, Novo Nordisk
In This Article:
Allurion catapulted Friday after the company said it plans to test its weight-loss technology with an obesity drug.
Oops, something went wrong
Unlock stock picks and a broker-level newsfeed that powers Wall Street.
Allurion catapulted Friday after the company said it plans to test its weight-loss technology with an obesity drug.